Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Privia Health Group, Inc. Market Cap
From what 7 stock analysts predict, the share price for Privia Health Group, Inc. (PRVA) might increase by 47.44% in the next year. This is based on a 12-month average estimation for PRVA. Price targets go from $27.00 to $35.00. The majority of stock analysts believe PRVA is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
PRVA is a stock in Technology which has been forecasted to be worth $30.86 as an average. On the higher end, the forecast price is $35.00 USD by andrew mok cfa from UBS and on the lower end PRVA is forecasted to be $27.00 by jeffrey garro from Stephens.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| sean dodge RBC Capital | Buy | $28.0 | maintained | Feb 16, 2024 |
| constantine davides JMP Securities | Buy | $27.0 | maintained | Jan 31, 2024 |
| adam ron Bank of America Securities | Buy | $27.0 | reiterated | Jan 30, 2024 |
| jessica tassan Piper Sandler | Buy | $35.0 | rated | Jan 30, 2024 |
| whit mayo Leerink Partners | Buy | $33.0 | reiterated | Jan 29, 2024 |
| jailendra singh Truist Financial | Buy | $32.0 | maintained | Jan 4, 2024 |
| david larsen BTIG | Buy | $30.0 | maintained | Jan 1, 2024 |
| lisa gill J.P. Morgan | Buy | $38.0 | maintained | Nov 17, 2023 |
| gary taylor TD Cowen | Buy | $30.0 | maintained | Nov 6, 2023 |
| brian tanquilut Jefferies | Buy | $33.0 | maintained | Nov 6, 2023 |
| richard close Canaccord Genuity | Buy | $41.0 | maintained | Nov 3, 2023 |
| jeffrey garro Stephens | Buy | $27.0 | maintained | Oct 30, 2023 |
| elizabeth anderson cfa Evercore ISI | Buy | $26.0 | maintained | Oct 11, 2023 |
| a.j. rice Credit Suisse | Buy | $41.0 | maintained | Aug 25, 2023 |
| jonathan yong Credit Suisse | Buy | $41.0 | reiterated | Jun 22, 2023 |
| andrew mok cfa UBS | Buy | $35.0 | maintained | May 9, 2023 |
| michael craig jones Stifel Nicolaus | Buy | $34.0 | maintained | Mar 1, 2023 |
| jamie perse Goldman Sachs | Buy | $32.0 | initiatedcoverage | Feb 3, 2023 |
| david s macdonald Truist Financial | Buy | $48.0 | maintained | Aug 12, 2022 |
| sean wieland Piper Sandler | Buy | $44.0 | maintained | Aug 12, 2022 |
Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings. It offers technology and population health tools to enhance independent providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; single-TIN medical group that facilitates payer negotiation, clinical integration and alignment of financial incentives; accountable care organization, which engage patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect with new patient populations and create custom contracts. The company was founded in 2007 and is headquartered in Arlington, Virginia. Privia Health Group, Inc. is a subsidiary of Brighton Health Group Holdings, LLC.
When did it IPO
2021
Staff Count
964
Country
United States
Sector/Industry
Healthcare/Health Information Services
CEO
Mr. Parth Mehrotra
Market Cap
$2.47B
In 2023, PRVA generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that PRVA's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
NTLA-USD
$27.74
$51.91
PSMT-USD
$80.24
PRFT-USD
$70.33
BMBL-USD
$13.1
$6.62
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
